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markers are better reflective of acute 
injury of tubular cells than of chronic 
interstitial damage. Thus, in chronic 
slowly progressive diseases, one should 
not expect a signifi cant increase in urinary 
excretion of markers refl ective of severe 
acute tubular-cell damage. At present, no 
solid data are available in support of a role 
for tubulointerstitial biomarkers in 
routine clinical use for the follow-up of 
CKD. Tests that can measure  per se the 
actual tubular function instead of acute 
tubular-cell damage may eventually be 
useful in assessment of chronic tubulo-
interstitial disease. 
 The question arises of how one can 
measure renal function to assess the effi  -
cacy of treatment intended to dampen the 
progression of renal damage. Creatinine 
and its derivative formulae, and creatinine 
clearance, are not the best markers to 
gauge renal function in the presence of 
proteinuria. 10 Th e use of low-molecular 
weight proteins, such as cystatin C, also 
does not add much value to assessment of 
renal function. Even when cystatin C and 
plasma creatinine together were taken into 
the equation, they were found to be insen-
sitive in detecting low-level reduction in 
the nephron mass, parti cularly in patients 
with well-preserved renal  function. 11 – 13 
 Finally, the experience of decades indi-
cates that the direct measure of glomerular 
fi ltration rate seems ideally suited to assess 
renal function. However, the routine use 
of exogenous substances poses a dilemma. 
Simplified radioisotopic methods have 
been proposed, which may be of real prac-
tical use in nephrology centers where a 
large number of patients can be seen. Th us, 
it seems that routine estimation of renal 
function can be gauged by measurement 
of plasma creatinine or cystatin C and their 
derivative formulae, but periodic checking 
of the true glomerular filtration rate is 
advisable, and the use of tubular markers 
to assess the  progression of diabetic neph-
ropathy and thus to infl uence therapeutic 
regimens seems premature at present. 
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 Vascular calcifi cation is highly prevalent 
in patients with kidney disease and is 
associated with increased risk of cardio-
vascular events and death. 1 Once thought 
to be a passive degenerative process, vas-
cular calcifi cation is now known to be a 
highly orchestrated process characterized 
by significant phenotypic changes and 
molecular reprogramming that entrains a 
repertoire of transcription factors and 
osteogenic programs. 
 Th ere are multiple mechanisms for vas-
cular calcifi cation. Particularly relevant to 
vascular calcifi cation in patients with kid-
ney disease are the mechanisms related to 
increased phosphate. 2 Elevated serum 
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 Phosphate-induced vascular calcification, characterized by 
induction of osteogenic programs, mineral vesicle release, and 
apoptosis, is prevalent in patients with kidney disease. Zhao  et al. 
provide a mechanistic link between phosphate-induced calcification 
and increased mitochondrial membrane potential, increased 
mitochondrial reactive oxygen species, activation of the nuclear 
factor-  B pathway, and subsequent expression of osteogenic genes 
and vascular mineralization. This link clarifies the intracellular 
mechanism of vascular calcification and may allow exploration of 
antioxidants as therapeutic agents for vascular calcification. 
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phosphorus is associated with increased 
calcifi cation scores, increased risk of car-
diovascular events, and all-cause mortal-
ity. Interventions aimed at lowering serum 
phosphorus concentrations may reduce 
the risk of cardiovascular events and 
improve survival. Over the past decade, 
multiple  in vitro and  in vivo experimental 
models have been developed to study the 
mechanisms of phosphate-induced vas-
cular calcifi cation. 
 Increased levels of phosphate induce 
calcifi cation in smooth muscle cells in a 
dose- and time-dependent fashion. Phos-
phate entry into vascular smooth muscle 
cells is mediated via the type III sodium-
dependent phosphate cotransporters Pit-1 
and Pit-2. Pit-1 seems to be expressed 
more abundantly in human vascular 
smooth muscle cells. 3 Incubation of vas-
cular smooth muscle cells in high-phos-
phate medium induces phosphate uptake 
into the cells and increased calcifi cation. 
Th is is an active process characterized by 
phenotypic changes of vascular smooth 
muscle cells into osteochondrogenic-like 
cells and the elaboration of a repertoire of 
osteogenic signals, including increased 
expression of Runx2 / Cbfa1 and osteopon-
tin. Treatment of vascular smooth muscle 
cells with a competitive inhibitor of the 
sodium-dependent phosphate cotrans-
porter phosphonormic acid causes a dose-
dependent inhibition of phosphate uptake 
and calcifi cation and abrogates the osteo-
genic program (increased expression of 
Runx2 / Cbfa1 and osteopontin). 3 Further 
experiments in which the type III sodium-
dependent phosphate cotransporter (Pit-1) 
was knocked down showed that Pit-1 
knockdown cells treated with high levels 
of phosphate exhibited reduced phosphate 
uptake, decreased levels of calci fi cation, 
and decreased expression of osteogenic 
markers compared with control cells incu-
bated in the same medium. 3 Furthermore, 
restoration of phosphate uptake in Pit-1 
knockdown cells by overexpression of 
mouse Pit-1 rescued elevated phosphate-
induced mineralization.  In vivo studies 
have also supported a role of phosphorus 
in vascular calcifi cation. Uremic mice fed 
a high-phosphorus diet show increased 
expression of Pit-1 and Runx2 in calcifi ed 
aorta, and treatment with phosphate bind-
ers attenuated this process. 
 Another mechanism of phosphate-
induced vascular calcifi cation includes 
smooth-muscle-cell apoptosis and matrix 
vesicle formation. In conditions of ele-
vated calcium and phosphate, vascular 
smooth muscle cells undergo apoptosis 
and phenotypic changes into osteo /
 chondrocytic-like cells releasing vesicles 
that contain preformed crystalline apatite 
crystals. 2 Phosphate-induced calcifi cation 
is initiated by the release of membrane-
bound matrix vesicles from living cells 
and apoptotic bodies from dying cells. 
Vesicles released by vascular smooth mus-
cle cells aft er prolonged exposure to cal-
cium and phosphate contain preformed 
basic calcium phosphate and calcify exten-
sively. In  ex vivo experiments, human 
arterial rings from predialysis and dialysis 
patients, but not from healthy control sub-
jects, showed signifi cant accumulation of 
calcium with long-term exposure to ele-
vated calcium and / or phosphate, suggest-
ing perhaps that the uremic environment 
compromises the calcifi cation-inhibitory 
mechanisms in the vessel wall. 4 Calcifi ed 
arterial rings from predialysis and dialysis 
patients had increased smooth muscle 
loss, increased vascular smooth muscle-
derived vesicles, and increased apoptosis, 
and treatment with a pan-caspase inhibi-
tor, ZVAD, ameliorated calcification. 4 
Under conditions of long-term exposure 
to elevated calcium and phosphorus, the 
majority of vascular smooth muscle cells 
in normal vessels exhibited extensive 
intracellular mitochondrial damage and 
calcifi cation, whereas the mitochondria of 
vascular smooth muscle cells in dialysis 
vessels were intact. 4 Th is provides evi-
dence that dysregulated divalent ion 
homeostasis may compromise mitochon-
drial architectural integrity. All the above 
taken together suggests that disturbances 
in divalent ion homeostasis activate 
calcifica tion mechanisms, leading to 
enhanced expression of osteogenic mark-
ers, increased vesicle release, apoptosis, 
and phenotypic changes in the vascular 
smooth muscle cell. 
 Oxidative stress generally represents the 
imbalance between increased production 
of reactive oxygen species (ROS) and the 
reduction in expression and / or activity of 
cellular antioxidant defense mechanisms 
(such as superoxide dismutase, catalase, 
glutathione peroxidase, peroxiredoxin, 
and sulfi redoxin). Sources of ROS include 
leakage of activated oxygen from mito-
chondria during oxidative phosphoryla-
tion and superoxide-producing enzymes 
such as xanthine oxidase, NADPH oxi-
dases, and cytochrome P450. Distur-
bances in the normal redox state at the 
cellular or tissue level can lead to damage 
through the production of peroxides and 
free radicals. At low levels, some oxidative 
species, however, act as messengers, a 
phenomenon oft en referred to as redox 
signaling. 
 Oxidative stress is commonly observed 
in patients with kidney disease. Although 
the association between oxidative stress 
and vascular calcifi cation has been noted 
in clinical epidemiology for a while, evi-
dence linking oxidative stress to activa-
tion of osteogenic programs and vascular 
calcifi cation has started to emerge only 
relatively recently. Hydrogen peroxide 
(H 2 O 2 ), which is a cell-permeable ROS 
(and a proinfl ammatory second messen-
ger), was shown to induce osteogenic 
gene expression, suppress smooth muscle 
cells ’ molecular signature, and induce 
calcifi cation. 5 H 2 O 2 -induced calcifi ca-
tion was abrogated in Runx2 knock-
down cells, indicating that the mechanism 
of H 2 O 2 -induced calcifi cation is Runx2 
dependent. H 2 O 2 -activated phosphatidyl-
inositol-3  -kinase – AKT signaling, but 
not extracellular signal-regulated kinase 
or phospholipase C   signaling, is 
required for H 2 O 2 -induced vascular 
smooth muscle calcifi cation. A recent 
study showed that H 2 O 2 is increased and 
colocalizes with the osteogenic transcrip-
tion factors Msx2 and Runx2 in calcifi ed 
human aortic valves. 6 In these valves 
H 2 O 2 production is the result of uncoupl-
ing of nitric oxide synthases (and not 
NADPH oxidase), and reduced expre-
ssion / activity of cellular antioxidant 
mechanisms, including superoxide dis-
mutase and catalase. 
 Zhao and collaborators 7 (this issue) 
extend the above fi ndings and examine 
the eff ect of   -glycerophosphate (BGP)-
induced calcifi cation on mitochondrial 
membrane potential, mitochondrial ROS, 
and the nuclear factor-  B (NF-  B) path-
way in bovine aortic smooth muscle cells 
and in adenine-fed rats. Th e investigators 
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report that BGP increased calcifi cation by 
increasing mitochondrial membrane 
potential and consequently increasing 
mitochondrial ROS, specifi cally superox-
ide (O 2 ). They show that blockade of 
mitochondrial ROS abrogates BGP-
induced calcifi cation, and that it reduced 
the expression of the osteogenic markers 
Cbfa1 and Msx2. Th e investigators also 
show that BGP activates the NF-  B path-
way with increased IKK  phosphoryla-
tion, I  B  degradation, and nuclear 
translocation of p65 and that blockade of 
mitochondrial ROS abrogates that eff ect. 
Adenoviral overexpression of I  B  and 
knockdown of p65 reduced BGP-induced 
calcium deposition in these cells. The 
authors also examined the eff ect in ade-
nine-fed rats and show that uremic rats 
developed increased calcium deposition, 
increased mitochondrial ROS levels, 
decreased I  B  , and increased nuclear 
translocation of p65, and that blockade of 
mitochondrial ROS by the use of 
MnTMPyP (Mn(III)tetrakis(1-methyl-4-
pyridyl)porphyrin pentachloride), a 
superoxide dismutase / catalase mimetic, 
abrogates that eff ect. BGP-induced calci-
fi cation may not be mediated principally 
by ROS produced through NADPH oxi-
dase or xanthine oxidase, as  pharmacologic 
blockade of these pathways has no eff ect 
on calcifi cation. 
 Th e importance of the study by Zhao 
and collaborators 7 is that it identifi es BGP 
as an inducer of H 2 O 2 , and more specifi -
cally mitochondrial superoxide (O 2 •–) 
( Figure 1 ). Th is novel link between BGP, a 
phosphate donor, and oxidative stress 
(both are prevalent in patients with kidney 
disease, and both are implicated in the 
pathobiology of vascular calcification) 
could have important clinical and thera-
peutic implications. Th e work is conceptu-
ally coherent and contributes to an 
enhanced understanding of the intracel-
lular mechanism of phosphate-induced 
vascular calcification in cell-culture 
models and  in vivo . Previous studies have 
linked oxidative stress and activation of 
the NF-  B pathway, and it has been pro-
posed that this is probably required for 
increased cellular survival in response to 
oxidative stress-induced cell damage and 
death. 8 Tumor necrosis factor-  (TNF-  ), a 
pro-osteogenic cytokine, stimulates perox-
ide production through NADPH oxidases 
and leads to increased generation of perox-
ide signals elaborated from mitochondrial 
activity and subsequently enhanced expres-
sion of membranous ossification pro-
grams (BMP-2, Msx2, Wnt3a, Wnt7a, and 
alkaline phosphatase in the arterial 
wall). 9,10 Th e elaboration of these mem-
branous ossifi cation programs (Msx2 –
 canonical Wnt signaling cascades), which 
are dependent on peroxide signals elabo-
rated from mitochondrial activity and 
downstream of TNF-stimulated NADPH 
oxidases, is also NF-  B dependent. 9,10 
Th e convergence of both phosphate and 
TNF-  (at least in part) on mitochondria-
generated ROS and subsequent activation 
of the NF-  B pathway suggest that this 
axis may be central to the pathobiology 
of calcifi cation. It would be interesting to 
know whether other procalcifi c or pro-
osteogenic moieties in patients with kid-
ney disease also stimulate mitochondrial 
oxidative stress. Further studies are 
needed to clarify the eff ect of mitochon-
drial ROS blockade on phosphate entry 
into the cell (via Pit-1 or other mecha-
nisms), mineral vesicle formation, apop-
tosis, and the canonical Wnt signaling 
pathway. 
 Finally, the study by Zhao  et al. 7 
expands our understanding of phosphate-
induced vascular calcifi cation; it deline-
ates a clear link between phosphate, 
mitochondrial oxidative stress, and the 
NF-  B pathway and paves the way for 
future research to further elucidate the 
intracellular mechanisms of phosphate-
induced vascular calcifi cation. Th is eff ort 
may eventually lead to the exploration of 
antioxidants as therapeutic agents for 
vascular calcifi cation. 
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 Figure 1  |  Phosphate-induced vascular calcification is mediated through activation of 
mitochondrial reactive oxygen species, and p65 nuclear translocation. Phosphate entry 
into the cell occurs via Pit-1 or possibly other transport mechanisms. Phosphate stimulates 
mitochondrial membrane potential and leads to increased production of reactive oxygen 
species (ROS). Superoxide (O 2 
•–), an ROS, activates the nuclear factor-  B (NF-  B) pathway with 
I  B  phosphorylation and subsequent proteasome degradation. The activated NF-  B is then 
translocated into the nucleus, where it binds to specific sequences of DNA and leads to increased 
expression of osteogenic transcription factors. The activation of membranous ossification 
programs leads to phenotypic changes in the cell as well as the release of membrane vesicles and 
apoptotic bodies, both containing hydroxyapatite crystals. 
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 What are the possible explanations of 
the inconsistent results obtained with 
these biomarkers? Some studies 2,3 show 
AUC values greater than 0.9 but, although 
truly positive, suff er from problems of 
generalizability, as they include homo-
geneous populations with a well-defi ned 
single injury to the kidney and with little 
or no additional comorbidity. In more 
heterogeneous populations such as adult 
cardiac surgery and, certainly, general 
ICU patients, the performance of biomar-
kers to detect AKI declines rapidly, with 
much lower AUC values. 1,4,5 Th e poor 
performance of urinary biomarkers in 
more general clinical conditions has 
recently been confirmed by Metzger 
 et al. 6 and could be overcome only by use 
of a panel of 20 urinary peptides. Th e 
novelty of the paper by Endre  et al. 1 is 
their attempt to evaluate whether specifi c 
biomarkers might perform better in spe-
cifi c clinical conditions — for example, in 
patients with versus without preexisting 
kidney disease, or with diff ering (pre-
sumed) timing of the kidney injury. 
Although this strategy indeed improved 
the results, enthusiasm is tempered by 
some more in-depth considerations. 
First, these new  ‘ categorized criteria ’ are 
 ‘ predictions of the past ’ and need to be 
validated in diff erent populations. Expe-
rience teaches that diagnostic accuracy 
plummets at such validation procedures. 
In addition, all the biomarkers in the 
EARLYARF trial have been determined 
in nearly ideal research environments. 
Th e switch to commercial kits will fur-
ther add to the diagnostic inaccuracy, 
along with the variability of the cutoff  
values of diff erent markers as reported in 
many studies. 7  Second, although the 
stratifi cation criteria applied by Endre 
 et al. 1 — underlying kidney function and 
timing of insult — seem to make sense, 
the time to insult had to be estimated for 
a substantial part of the population, and 
in clinical practice this information is 
oft en lacking. Th e majority of deaths aft er 
AKI occur in patients in whom the time 
of the renal insult is unknown. 8 Moreo-
ver, not knowing the time of insult is 
most problematic in patients with smol-
dering disease, such as sepsis — exactly 
the patient population that would bene-
fi t most from a robust AKI marker. In 
 “ When you search in the stars for 
what lies before your feet you risk to 
stumbling over the cobblestones. ” 
 freely translated from 
Schopenhauer 
 (Source: Internet quotes) 
 Urinary biomarkers in the fi eld of acute 
kidney injury (AKI) are a hot topic. A 
PubMed search using the terms  ‘ biological 
marker, urine ’ and  ‘ kidney injury, acute ’ 
revealed 158 papers on humans published 
in the past 24 months. Th e large majority, 
as well as their accompanying editorials, 
start or end with a statement that  ‘ urinary 
biomarker X ’ is very promising for clinical 
management of AKI and detection of 
renal damage before a fall in glomerular 
 fi ltration rate is noticeable from a rise in 
serum creatinine (SCr) and / or urinary 
output. Do the data really support this 
optimistic view, and can unrestricted 
implementation of biomarkers in clinical 
practice be recommended at present? 
 Th e paper by Endre  et al. 1 in this issue of 
 Kidney International does not support this 
view. In patients admitted to the intensive 
care unit (ICU), the areas under the 
receiver operating characteristic curves 
(AUCs) of biomarkers were compared for 
diagnosis and prediction of AKI, need of 
renal replacement therapy (RRT), and / or 
mortality. Th e overall performance of the 
six biomarkers was poor, taking into 
account that an AUC of 0.5 reflects the 
diagnostic accuracy of random allocation. 
 Figure 1 and  Table 1 show the AUC 
 values of diff erent biomarkers, clinical 
scores, and routine biochemical para-
meters (RIFLE classifi cation or Screa) as 
retrieved from human studies on AKI. A 
huge variation in the values is obvious. 
 How to use biomarkers efficiently 
in acute kidney injury 
 Norbert H.  Lameire 1 ,  Raymond C.  Vanholder 1 and  Wim A.  Van Biesen 1 
 We discuss the performance of novel biomarkers in acute kidney injury 
(AKI). Comparison of the areas under the receiver operating 
characteristic curves of several biomarkers with some clinical and / or 
routine biochemical outcome parameters reveals that none of the 
biomarkers has demonstrated a clear additional value beyond the 
traditional approach in clinical decision making in patients with AKI.  
Unscrutinized use of these biomarkers may distract from adequate 
clinical evaluation and carries the risk of worse instead of better 
patient outcome. 
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